Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Consensus "Moderate Buy": Six analysts cover COYA (five buy, one sell) and the average 12‑month target price is $16.00.
• Recent results and metrics: the stock opened at $4.78 with a market cap of $112.14M, and the company reported an EPS miss (‑$0.34 vs. ‑$0.08 expected) despite revenue of $3.96M; analysts forecast a ‑1.15 EPS for the year.
• Company profile and pipeline: Coya is a clinical‑stage biotech targeting the UNC‑45A pathway, advancing COY‑001 for fibrotic diseases and COY‑002 toward the clinic for certain solid tumors.

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $16.00.

COYA has been the subject of several recent analyst reports. D. Boral Capital restated a "buy" rating and issued a $15.00 price target on shares of Coya Therapeutics in a research note on Friday, April 10th. Wall Street Zen upgraded Coya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Weiss Ratings reissued a "sell (d-)" rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, March 23rd. Finally, Chardan Capital reaffirmed a "buy" rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Monday, March 16th.

Institutional Trading of Coya Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of COYA. Prosperity Wealth Management Inc. increased its holdings in shares of Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company's stock valued at $136,000 after buying an additional 3,350 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Coya Therapeutics in the 3rd quarter worth $28,000. CIBC Private Wealth Group LLC acquired a new position in shares of Coya Therapeutics in the 4th quarter worth $47,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Coya Therapeutics during the fourth quarter worth $66,000. Finally, Lantern Wealth Advisors LLC acquired a new stake in shares of Coya Therapeutics during the third quarter worth $66,000. Institutional investors own 39.75% of the company's stock.

Coya Therapeutics Price Performance

NASDAQ COYA opened at $4.78 on Friday. The company's fifty day moving average price is $4.53 and its two-hundred day moving average price is $5.29. The company has a market capitalization of $112.14 million, a price-to-earnings ratio of -3.76 and a beta of 0.51. Coya Therapeutics has a 12 month low of $3.71 and a 12 month high of $7.75.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its earnings results on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.The firm had revenue of $3.96 million during the quarter, compared to analyst estimates of $1.93 million. As a group, analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.